NKGen Biotech, Inc. (NKGN) Key Metrics
NKGN key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNKGN returns How much profit the business earns on the capital it uses.
NKGN financial health Debt, liquidity and how easily interest is covered.
NKGN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NKGN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NKGN price vs earnings per share
NKGN key metrics
2021–2025| 2025 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $1.4M | — | — | — |
| Earnings yield | −3,072.2% | — | — | — |
| Free cash flow yield | −1,448.5% | — | — | — |
| Share price at fiscal year-end | $0.05 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | — | — | — |
| Earnings per share | −$1.54 | — | — | — |
| Operating cash flow per share | −$0.72 | — | — | — |
| Free cash flow per share | −$0.72 | — | — | — |
| Capex per share | $0.00 | — | — | — |
| Shares outstanding | 28.8M | — | — | — |
| Returns & profitability | ||||
| Return on invested capital (ROIC) | — | — | −142.2% | −127.3% |
| Return on assets (ROA) | −536.6% | −505.6% | −155.5% | −128.7% |
| Return on tangible assets | — | −506.2% | −164.8% | −129.4% |
| Financial health | ||||
| Total debt | — | $19.9M | $12.0M | $52.0M |
| Cash & short-term investments | — | $26,000 | $117,000 | $351,000 |
| Net debt | — | $19.9M | $11.9M | $51.6M |
| Debt / equity | — | — | 7.70 | — |
| Debt / assets | — | 1.21 | 0.74 | 2.88 |
| Current ratio | — | 0.05 | 0.02 | 0.01 |
| Quick ratio | — | 0.06 | 0.01 | 0.01 |
| Interest coverage | -9.9 | -39.9 | -10.6 | -16.6 |
| Working capital | — | −$37.5M | −$14.4M | −$55.1M |
| Invested capital | — | −$38.8M | $13.5M | $13.6M |
| Tangible asset value | — | −$58.8M | $1.5M | −$38.1M |
| Net current asset value | — | −$73.2M | −$14.4M | −$55.5M |
| Capital allocation | ||||
| Capex / revenue | — | — | 211.7% | 107.7% |
| Capex / depreciation | 0.00 | 0.04 | 0.13 | 0.37 |
| Stock-based compensation / revenue | — | — | 89.6% | 21.8% |
| R&D / revenue | — | — | 21,748.1% | 3,444.1% |
| SG&A / revenue | — | — | 9,946.8% | 1,780.5% |
| Efficiency | ||||
| Days sales outstanding | — | — | 386.3 | 57.4 |
| Days of inventory on hand | — | -17.7 | 3,092.4 | 2,092.7 |
| Days payables outstanding | — | 1,822.7 | 27,263.5 | 20,853.7 |
| Cash conversion cycle (days) | — | — | -23,784.8 | -18,703.6 |
| Receivables turnover | 0.00 | 0.00 | 0.94 | 6.36 |
| Payables turnover | — | 0.20 | 0.01 | 0.02 |
| Inventory turnover | — | — | 0.12 | 0.17 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.02 |
| Average receivables | $25,000 | $61,000 | $81,500 | $67,000 |
| Average payables | — | $6.0M | $1.3M | $1.7M |
| Average inventory | — | −$58,500 | $152,500 | $172,000 |
| Intangibles / total assets | 0.0% | 0.6% | 0.6% | 0.5% |
Computed from NKGN's annual financial statements (latest annual report filed October 8, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NKGN valuation and financial ratios
See the NKGN income statement, the NKGN chart for price history, or the NKGN stock overview for the latest quote and news.
NKGN key metrics FAQ
What is NKGen Biotech's free cash flow yield?
NKGen Biotech generated -$20.9 million of free cash flow in fiscal 2025, a free cash flow yield of −1,448.5% on its market value at year-end ($1.4 million).